121 related articles for article (PubMed ID: 32427381)
1. Systemic blockade of ACVR2B ligands attenuates muscle wasting in ischemic heart failure without compromising cardiac function.
Szabó Z; Vainio L; Lin R; Swan J; Hulmi JJ; Rahtu-Korpela L; Serpi R; Laitinen M; Pasternack A; Ritvos O; Kerkelä R; Magga J
FASEB J; 2020 Aug; 34(8):9911-9924. PubMed ID: 32427381
[TBL] [Abstract][Full Text] [Related]
2. Systemic Blockade of ACVR2B Ligands Protects Myocardium from Acute Ischemia-Reperfusion Injury.
Magga J; Vainio L; Kilpiö T; Hulmi JJ; Taponen S; Lin R; Räsänen M; Szabó Z; Gao E; Rahtu-Korpela L; Alakoski T; Ulvila J; Laitinen M; Pasternack A; Koch WJ; Alitalo K; Kivelä R; Ritvos O; Kerkelä R
Mol Ther; 2019 Mar; 27(3):600-610. PubMed ID: 30765322
[TBL] [Abstract][Full Text] [Related]
3. Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis.
Castillero E; Akashi H; Najjar M; Ji R; Brandstetter LM; Wang C; Liao X; Zhang X; Sperry A; Gailes M; Guaman K; Recht A; Schlosberg I; Sweeney HL; Ali ZA; Homma S; Colombo PC; Ferrari G; Schulze PC; George I
Am J Physiol Heart Circ Physiol; 2020 Feb; 318(2):H378-H390. PubMed ID: 31886717
[TBL] [Abstract][Full Text] [Related]
4. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
Hulmi JJ; Nissinen TA; Räsänen M; Degerman J; Lautaoja JH; Hemanthakumar KA; Backman JT; Ritvos O; Silvennoinen M; Kivelä R
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):417-432. PubMed ID: 29230965
[TBL] [Abstract][Full Text] [Related]
5. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
6. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia.
Huot JR; Pin F; Narasimhan A; Novinger LJ; Keith AS; Zimmers TA; Willis MS; Bonetto A
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1779-1798. PubMed ID: 33200567
[TBL] [Abstract][Full Text] [Related]
7. Activin type II receptor signaling in cardiac aging and heart failure.
Roh JD; Hobson R; Chaudhari V; Quintero P; Yeri A; Benson M; Xiao C; Zlotoff D; Bezzerides V; Houstis N; Platt C; Damilano F; Lindman BR; Elmariah S; Biersmith M; Lee SJ; Seidman CE; Seidman JG; Gerszten RE; Lach-Trifilieff E; Glass DJ; Rosenzweig A
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842316
[TBL] [Abstract][Full Text] [Related]
8. Direct Evidence that Myocardial Insulin Resistance following Myocardial Ischemia Contributes to Post-Ischemic Heart Failure.
Fu F; Zhao K; Li J; Xu J; Zhang Y; Liu C; Yang W; Gao C; Li J; Zhang H; Li Y; Cui Q; Wang H; Tao L; Wang J; Quon MJ; Gao F
Sci Rep; 2015 Dec; 5():17927. PubMed ID: 26659007
[TBL] [Abstract][Full Text] [Related]
9. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
10. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs.
Solagna F; Tezze C; Lindenmeyer MT; Lu S; Wu G; Liu S; Zhao Y; Mitchell R; Meyer C; Omairi S; Kilic T; Paolini A; Ritvos O; Pasternack A; Matsakas A; Kylies D; Wiesch JSZ; Turner JE; Wanner N; Nair V; Eichinger F; Menon R; Martin IV; Klinkhammer BM; Hoxha E; Cohen CD; Tharaux PL; Boor P; Ostendorf T; Kretzler M; Sandri M; Kretz O; Puelles VG; Patel K; Huber TB
J Clin Invest; 2021 Jun; 131(11):. PubMed ID: 34060483
[TBL] [Abstract][Full Text] [Related]
11. Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade.
Lautaoja JH; Lalowski M; Nissinen TA; Hentilä J; Shi Y; Ritvos O; Cheng S; Hulmi JJ
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E852-E865. PubMed ID: 30860875
[TBL] [Abstract][Full Text] [Related]
12. Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight.
Lee SJ; Lehar A; Meir JU; Koch C; Morgan A; Warren LE; Rydzik R; Youngstrom DW; Chandok H; George J; Gogain J; Michaud M; Stoklasek TA; Liu Y; Germain-Lee EL
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23942-23951. PubMed ID: 32900939
[TBL] [Abstract][Full Text] [Related]
13. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
14. Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass.
Goh BC; Singhal V; Herrera AJ; Tomlinson RE; Kim S; Faugere MC; Germain-Lee EL; Clemens TL; Lee SJ; DiGirolamo DJ
J Biol Chem; 2017 Aug; 292(33):13809-13822. PubMed ID: 28659341
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
16. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.
Barreto R; Kitase Y; Matsumoto T; Pin F; Colston KC; Couch KE; O'Connell TM; Couch ME; Bonewald LF; Bonetto A
Sci Rep; 2017 Oct; 7(1):14470. PubMed ID: 29089584
[TBL] [Abstract][Full Text] [Related]
17. A soluble activin receptor type IIB does not improve blood glucose in streptozotocin-treated mice.
Wang Q; Guo T; Portas J; McPherron AC
Int J Biol Sci; 2015; 11(2):199-208. PubMed ID: 25561902
[TBL] [Abstract][Full Text] [Related]
18. Treatment with Soluble Activin Receptor Type IIB Alters Metabolic Response in Chemotherapy-Induced Cachexia.
O'Connell TM; Pin F; Couch ME; Bonetto A
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31438622
[TBL] [Abstract][Full Text] [Related]
19. Dysfunctional and Proinflammatory Regulatory T-Lymphocytes Are Essential for Adverse Cardiac Remodeling in Ischemic Cardiomyopathy.
Bansal SS; Ismahil MA; Goel M; Zhou G; Rokosh G; Hamid T; Prabhu SD
Circulation; 2019 Jan; 139(2):206-221. PubMed ID: 30586716
[TBL] [Abstract][Full Text] [Related]
20. Exercise training decreases NADPH oxidase activity and restores skeletal muscle mass in heart failure rats.
Cunha TF; Bechara LR; Bacurau AV; Jannig PR; Voltarelli VA; Dourado PM; Vasconcelos AR; Scavone C; Ferreira JC; Brum PC
J Appl Physiol (1985); 2017 Apr; 122(4):817-827. PubMed ID: 28104751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
